LivaNova VNS Therapy shows 76% median seizure reduction at 36 months in study
LIVN•LivaNova said the CORE-VNS study showed a 76% median seizure reduction at 36 months among people treated with VNS Therapy for drug-resistant epilepsy.
1. Study results
LivaNova announced publication of the full 36-month CORE-VNS study results in Neuromodulation. The brief says seizure reductions emerged early and improved over time in children and adults, most responders maintained or improved their outcomes, and treatment improved quality of life and reduced seizure-related hospital use, with no new safety concerns identified.
